Safety and efficacy of COROPROTECT kit as an add-on therapy in the management of mild-to-moderate COVID-19: A randomized, placebo-controlled trial.

Ayu Pub Date : 2023-01-01 Epub Date: 2024-02-21 DOI:10.4103/ayu.ayu_92_22
Chetan Savaliya, Shridhar Pandya, Kamalesh Thumar, Dheeraj Nagore
{"title":"Safety and efficacy of COROPROTECT kit as an add-on therapy in the management of mild-to-moderate COVID-19: A randomized, placebo-controlled trial.","authors":"Chetan Savaliya, Shridhar Pandya, Kamalesh Thumar, Dheeraj Nagore","doi":"10.4103/ayu.ayu_92_22","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The constructive role of Ayurveda in managing COVID-19 has been widely discussed, with identified herbs showing immunomodulatory and anti-viral potential. However, clinical trials examining their safety and efficacy are limited.</p><p><strong>Aim: </strong>The aim of this study is to determine the efficacy of COROPROTECT kit, a proprietary Ayurvedic formulation, in COVID-19.</p><p><strong>Materials and method: </strong>Randomized, placebo-controlled trial with 312 mild to moderate hospitalized COVID-19 patients. Groups received COROPROTECT or placebo for 10 days alongside standard care.</p><p><strong>Results: </strong>The outcome measures included the number of days taken to reverse the reverse transcriptase-polymerase chain reaction (RT-PCR) status, reduction in symptoms and inflammatory markers. Fisher exact test was used to analyze the changes between categorical variables, whereas the comparative effect of therapy in both groups on inflammatory markers and safety biochemical parameters was analyzed using Student's <i>t</i> test. A total of 300 patients completed the study without any adverse events. The COROPROTECT kit group exhibited a statistically significant higher percentage of patients testing negative on days 4, 7, and 10 compared to the placebo group. A within group analysis showed that trial group to significantly reduced the levels of C-reactive protein (<i>P</i> = 0.03), lactate dehydrogenase (<i>P</i> < 0.001), and interleukin-6 (<i>P</i> = 0.01). Subjects of the trial group experienced complete relief from cough (69.33%), breathlessness (65.33%), and fatigue (62.67%) within 4 days. In contrast, the placebo group had 20%-40% of participants with mild symptoms persisting until day 10.</p><p><strong>Conclusion: </strong>This study suggests potential future implications, indicating a faster RT-PCR negativity, reduced COVID-19 severity, and inflammatory markers, along with early symptomatic recovery. The COROPROTECT kit proved safe, facilitating an accelerated clinical recovery compared to conventional care.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946664/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ayu","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ayu.ayu_92_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The constructive role of Ayurveda in managing COVID-19 has been widely discussed, with identified herbs showing immunomodulatory and anti-viral potential. However, clinical trials examining their safety and efficacy are limited.

Aim: The aim of this study is to determine the efficacy of COROPROTECT kit, a proprietary Ayurvedic formulation, in COVID-19.

Materials and method: Randomized, placebo-controlled trial with 312 mild to moderate hospitalized COVID-19 patients. Groups received COROPROTECT or placebo for 10 days alongside standard care.

Results: The outcome measures included the number of days taken to reverse the reverse transcriptase-polymerase chain reaction (RT-PCR) status, reduction in symptoms and inflammatory markers. Fisher exact test was used to analyze the changes between categorical variables, whereas the comparative effect of therapy in both groups on inflammatory markers and safety biochemical parameters was analyzed using Student's t test. A total of 300 patients completed the study without any adverse events. The COROPROTECT kit group exhibited a statistically significant higher percentage of patients testing negative on days 4, 7, and 10 compared to the placebo group. A within group analysis showed that trial group to significantly reduced the levels of C-reactive protein (P = 0.03), lactate dehydrogenase (P < 0.001), and interleukin-6 (P = 0.01). Subjects of the trial group experienced complete relief from cough (69.33%), breathlessness (65.33%), and fatigue (62.67%) within 4 days. In contrast, the placebo group had 20%-40% of participants with mild symptoms persisting until day 10.

Conclusion: This study suggests potential future implications, indicating a faster RT-PCR negativity, reduced COVID-19 severity, and inflammatory markers, along with early symptomatic recovery. The COROPROTECT kit proved safe, facilitating an accelerated clinical recovery compared to conventional care.

COROPROTECT 套件作为治疗轻度至中度 COVID-19 的附加疗法的安全性和有效性:随机安慰剂对照试验。
背景:阿育吠陀在控制 COVID-19 方面的建设性作用已被广泛讨论,已确定的草药具有免疫调节和抗病毒潜力。目的:本研究旨在确定COROPROTECT试剂盒(一种阿育吠陀专利配方)对COVID-19的疗效:随机安慰剂对照试验,312名轻度至中度住院COVID-19患者参加。各组接受 COROPROTECT 或安慰剂治疗 10 天,同时接受标准护理:结果测量包括逆转录酶聚合酶链反应(RT-PCR)状态逆转所需的天数、症状和炎症标志物的减少。费舍尔精确检验用于分析分类变量之间的变化,而两组治疗对炎症指标和安全生化指标的比较效果则采用学生 t 检验进行分析。共有 300 名患者完成了研究,未出现任何不良反应。与安慰剂组相比,COROPROTECT试剂盒组在第4、7和10天检测结果呈阴性的患者比例明显更高。组内分析显示,试验组显著降低了 C 反应蛋白(P = 0.03)、乳酸脱氢酶(P < 0.001)和白细胞介素-6(P = 0.01)的水平。试验组受试者在 4 天内完全缓解了咳嗽(69.33%)、呼吸困难(65.33%)和疲劳(62.67%)。相比之下,安慰剂组有 20%-40% 的受试者轻微症状持续到第 10 天:这项研究表明,RT-PCR 阴性反应更快,COVID-19 严重程度和炎症标志物降低,症状也能尽早恢复。事实证明,COROPROTECT 套件是安全的,与传统治疗相比,它能加快临床康复。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ayu
Ayu
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信